Lung cancer remains the primary cause of cancer-related mortality worldwide, with 5-year overall survival lingering at approximately 20%. Although targeted tyrosine kinase inhibitors and immune checkpoint inhibitors revolutionized thoracic oncology, acquired resistance inevitably emerges in advanced stages. Consequently, clinicians require innovative therapeutic modalities to overcome refractory tumor progression. The therapeutic emergence of ADCs in lung cancer represents a transformative milestone for patients with metastatic non-small cell lung cancer. These specialized pharmacological constructs combine the exquisite specificity of monoclonal antibodies with the potent cytotoxicity of chemotherapeutic agents. As a result, oncology teams can now deliver high concentrations of cytotoxic payloads directly to malignant cells while limiting systemic exposure.

Mechanisms of Action and Structural Foundations of ADCs in Lung Cancer

Antibody-drug conjugates employ a sophisticated tri-part design comprising a target-specific monoclonal antibody, a stable biochemical linker, and a cytotoxic payload. First, the antibody component recognizes specific tumor-associated antigens overexpressed on malignant cells. Upon antigen binding, the receptor-antibody complex undergoes endocytosis, transporting the drug conjugate into intracellular lysosomes. Lysosomal proteases subsequently cleave peptide linkers, or chemical degradation occurs, releasing the cytotoxic payload inside the cytoplasm. Furthermore, modern conjugates utilize membrane-permeable topoisomerase I inhibitors or tubulin disruptors that diffuse into neighboring antigen-negative tumor cells. Clinicians refer to this phenomenon as the bystander killing effect, which significantly mitigates the impact of intratumoral heterogeneity. In addition, next-generation bio-conjugation technologies maintain high drug-to-antibody ratios without compromising antibody stability or pharmacokinetic half-life. Therefore, these engineered constructs achieve sustained therapeutic drug levels within poorly vascularized tumor tissues. In contrast to conventional non-targeted cytotoxic chemotherapy, ADCs optimize therapeutic indices by substantially reducing non-specific damage to healthy peripheral organs. Thus, this targeted mechanism forms the pharmacological bedrock of modern ADC development across thoracic malignancies.

Targeting HER2 and MET in Metastatic Disease

Clinical trials have validated several molecular targets for antibody-drug conjugates in metastatic non-small cell lung cancer. Specifically, human epidermal growth factor receptor 2 mutations define a critical oncogenic subset of lung adenocarcinoma. Trastuzumab deruxtecan delivers a topoisomerase I inhibitor payload to HER2-expressing and HER2-mutated tumor cells. In pivotal clinical trials, trastuzumab deruxtecan generated durable objective response rates exceeding 50% in previously treated patients. Consequently, regulatory authorities granted accelerated approval for this agent in HER2-mutant metastatic disease. Similarly, the cellular-mesenchymal epithelial transition factor represents another clinically actionable target in thoracic oncology. Telisotuzumab vedotin targets c-MET using a monoclonal antibody linked to monomethyl auristatin E, an antimicrotubule payload. Furthermore, clinical investigators observed robust disease control when administering telisotuzumab vedotin to patients with c-MET-overexpressing, EGFR wild-type non-squamous non-small cell lung cancer. Therefore, international guidelines now endorse telisotuzumab vedotin as an effective subsequent-line therapy for this biomarker-defined population. These landmark approvals confirm that precise antigen identification through immunohistochemistry and next-generation sequencing remains mandatory for optimizing therapeutic selection in clinical oncology.

Addressing EGFR Mutations with TROP2-Directed Therapies

Patients with epidermal growth factor receptor mutations frequently face disease progression following frontline osimertinib or other third-generation tyrosine kinase inhibitors. Historically, systemic platinum-doublet chemotherapy offered modest progression-free survival benefits in this refractory setting. However, novel antibody-drug conjugates targeting trophoblast cell-surface antigen 2 provide a much more promising therapeutic alternative. For example, datopotamab deruxtecan incorporates an anti-TROP2 antibody coupled to a deruxtecan topoisomerase I inhibitor. Clinical data from late-phase trials demonstrate that datopotamab deruxtecan significantly prolongs progression-free survival compared to standard docetaxel in pre-treated non-small cell lung cancer. In addition, patients harboring actionable genomic alterations such as EGFR mutations derived notable benefit from this TROP2-directed approach. Moreover, the payload crosses the blood-brain barrier effectively, exerting clinically meaningful intracranial antitumor activity against cerebral metastases. Concurrently, sacituzumab tirumotecan demonstrates robust clinical efficacy in patients with refractory EGFR-mutant disease after targeted kinase inhibitor failure. Consequently, oncologists view TROP2-targeted ADCs as an essential sequencing strategy after conventional targeted therapies fail.

Managing Adverse Events and Unique Toxicity Profiles

Despite impressive therapeutic efficacy, antibody-drug conjugates produce distinctive off-target and on-target toxicities that require vigilant clinical oversight. Most notably, topoisomerase I inhibitor conjugates carry a recognized risk of drug-induced interstitial lung disease and pneumonitis. Therefore, pulmonologists and oncologists must screen patients regularly using high-resolution computed tomography scans and clinical symptom assessments. If radiographic evidence of interstitial lung disease appears, clinicians must immediately interrupt therapy and initiate systemic corticosteroid administration. In contrast, conjugates delivering monomethyl auristatin E, such as telisotuzumab vedotin, primarily induce peripheral neuropathy, fatigue, and ocular toxicities. Because of this, clinicians must perform baseline neurological examinations and monitor patients for sensory deficits at every treatment cycle. Additionally, gastrointestinal adverse events like nausea, stomatitis, and diarrhea occur frequently across multiple ADC classes. Proactive antiemetic prophylaxis and comprehensive oral care protocols substantially mitigate these bothersome side effects. Thus, multidisciplinary collaboration between thoracic oncologists, chest physicians, and oncology nurses ensures prompt toxicity detection, appropriate dose adjustments, and enhanced treatment adherence.

Overcoming Resistance and Future Horizons

Although antibody-drug conjugates improve progression-free intervals, tumors eventually develop acquired resistance through diverse biological pathways. Specifically, malignant cells may downregulate target cell-surface antigens, which impairs conjugate binding and subsequent internalization. Alternatively, cancer cells upregulate ATP-binding cassette transporter pumps, rapidly expelling cytotoxic payloads out of the intracellular compartment. Furthermore, secondary genomic mutations within payload targets, such as topoisomerase I alterations, can abrogate cytotoxic efficacy. To overcome these formidable escape mechanisms, pharmaceutical researchers are actively designing next-generation bispecific antibody-drug conjugates. These innovative molecules simultaneously engage two distinct antigens, such as EGFR and c-MET, enhancing tumor avidity and counteracting antigen loss. Moreover, scientists are exploring novel payload classes, including immune-stimulating compounds and targeted protein degraders, to bypass classic chemotherapeutic resistance. Similarly, clinicians are evaluating synergistic combination regimens integrating ADCs with immune checkpoint inhibitors or selective kinase inhibitors. As ongoing phase 3 clinical trials mature, these technological innovations will likely broaden therapeutic indications into earlier stages of lung cancer management.

Frequently Asked Questions

Which patients with lung cancer qualify for ADC therapy?

Currently, candidates for antibody-drug conjugate therapy include patients with metastatic non-small cell lung cancer possessing specific biomarkers after standard therapies fail. For example, clinicians prescribe trastuzumab deruxtecan for patients whose tumors harbor activating HER2 mutations. Additionally, patients with high c-MET protein overexpression may receive telisotuzumab vedotin. Furthermore, individuals with advanced EGFR-mutated disease who develop disease progression on tyrosine kinase inhibitors qualify for TROP2-directed conjugates like datopotamab deruxtecan in specialized oncology settings.

How do clinicians monitor and manage ADC-related interstitial lung disease?

Clinicians actively monitor patients receiving topoisomerase I inhibitor ADCs through regular high-resolution chest imaging and symptom screening at every cycle. If patients develop new or worsening pulmonary symptoms, such as non-productive cough or dyspnea, physicians must immediately withhold the conjugate. For symptomatic interstitial lung disease of grade 2 or higher, treatment guidelines mandate systemic corticosteroid therapy and permanent drug discontinuation. Early detection and multidisciplinary evaluation prevent serious complications and irreversible pulmonary fibrosis.

Why are bispecific antibody-drug conjugates being developed in lung cancer?

Biomedical researchers are developing bispecific antibody-drug conjugates to address tumor antigen heterogeneity and counteract acquired resistance in lung cancer. Because standard single-target conjugates rely on one surface marker, tumors frequently escape destruction through antigen downregulation. In contrast, bispecific ADCs bind two distinct receptors simultaneously, such as EGFR and c-MET, which increases avidity and ensures reliable payload delivery. Consequently, these dual-targeting constructs improve cellular internalization, minimize off-target toxicity, and effectively delay disease recurrence.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. It is not intended to replace consultation with a qualified medical professional or healthcare provider. The application of clinical concepts, diagnostic algorithms, and pharmacologic choices must always be tailored to the specific circumstances of each individual case, considering local drug approvals, contraindications, and evolving treatment guidelines. Healthcare professionals must exercise their independent clinical judgment, and patients should never disregard professional medical advice or delay seeking it because of something they have read here. Refer to the latest local and national guidelines for clinical practice.

References

1. Pickett H et al. Emerging landscape of antibody-drug conjugates in lung cancer: a clinical review. Trends Cancer. 2026 Oct 13. doi: undefined. PMID: 42869767.
2. Li BT, Smit EF, Goto Y, et al. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022;386(3):241-251.
3. Tarantino P, Ricciuti B, Pradhan SM, Tolaney SM. Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Nat Rev Clin Oncol. 2023;20(8):558-576.
4. Jänne PA, Baik C, Su WC, et al. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC: HERTHENA-Lung01. J Clin Oncol. 2024;42(1):49-59.